This study is looking into a new way to treat moderate to severe rheumatoid arthritis (RA) using a device that delivers ultrasound stimulation to the spleen. The goal is to see if this non-invasive (no needles or surgery) treatment can help reduce inflammation. You would continue taking your current conventional synthetic DMARD (disease-modifying anti-rheumatic drug) throughout the study. There are two groups receiving different settings of the ultrasound stimulation and one group receiving a sham (inactive) stimulation. Researchers will compare how well the active treatments work against the sham treatment by measuring changes in your RA symptoms over 12 weeks. The study plans to include at least 60 participants.

Study design

This interventional study will enroll at least 60 participants and has three groups: two receiving active ultrasound stimulation and one receiving sham (inactive) stimulation. All participants will also be taking a conventional synthetic DMARD.

What's involved

You would receive daily non-invasive ultrasound stimulation of the spleen for 20 minutes once per day. You would also continue taking your conventional synthetic DMARD at a stable dose throughout the study.

Compensation

Not stated in the trial record.

Follow-up

The main measurements for the study will be taken at 12 weeks after starting the treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.